U.S. senators want five drugmakers to account for increases in the price of a drug that's used to reverse the effects of prescription and illegal opioids, as the number of Americans overdosing on painkillers and heroin has skyrocketed in recent years.
Senators Susan Collins, a Maine Republican, and Claire McCaskill, a Missouri Democrat, wrote to Pfizer Inc., Mylan NV, Amphastar Pharmaceuticals Inc., Adapt Pharma Inc. and Kaleo Inc., asking them to explain price changes to the drug, naloxone.
They cited a report in Politico that at least one version of the drug has risen in price by as much as 17-fold in the last two years. Collins is the chairwoman of the Senate Special Committee on Aging and McCaskill is the panel's top Democrat.
"As we work to address a complex public health crisis, it is important that naloxone, a potentially lifesaving tool, be accessible," the senators wrote in a letter dated June 3.
Adapt hasn't raised its price since its version was approved last year, said Thom Duddy, a spokesman. Amphastar said it offers nine states rebates on the drug, and it and Pfizer both said they would cooperate with the inquiry, as did Pfizer. Kaleo and Mylan didn't immediately have a comment on the senators' questions.
The senators also want to know what the companies are doing to preserve access to the drug, which hospitals have said they've had trouble obtaining.
More here
DelMarVa's Premier Source for News, Opinion, Analysis, and Human Interest Contact Publisher Joe Albero at alberobutzo@wmconnect.com or 410-430-5349
2 comments:
It happens every time a drug becomes more popular.
The market drives the pricing. The producers push the market price up at every opportunity. If it's outrageous, it's called profiteering.
Post a Comment